Clinical trial
A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years
NCT04422366 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- April 28, 2020
- Completion date
- September 15, 2029
- Enrollment
- 8,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ais, cervical cancer, cin1, cin2, cin3, genital wart, vaginal cancer, vain1, vain2, vain3, vin 1, vin 2, vin 3, vulvar cancer